Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Rooney · SciRah

Researcher profile · Semantic Scholar

C. Rooney

Share profile

C. Rooney — researcher profile on SciRah

h-index: 20
Works: 65
Citations: 1,983

Most-cited papers

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
P. Gavine, L. Mooney, E. Kilgour, A. Thomas +8 more
2012Cancer Research472 citations Open access
Semantic Scholar
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial
A. Pearson, E. Smyth, I. Babina, M. T. Herrera-Abreu +23 more
2016Cancer Discovery250 citations Open access
Semantic Scholar
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Rebecca P A Ellston +13 more
2017Science Translational Medicine158 citations Open access
Semantic Scholar
A Phase 1b Open Label Multicentre Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
P. Paik, R. Shen, M. Berger, D. Ferry +10 more
2017Clinical Cancer Research114 citations Open access
Semantic Scholar
The Rac activator STEF (Tiam2) regulates cell migration by microtubule‐mediated focal adhesion disassembly
C. Rooney, Gavin R. M. White, Alicja Nazgiewicz, S. Woodcock +3 more
2010EMBO Reports113 citations Open access
Semantic Scholar
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
Lynda Vuong, E. Kouverianou, C. Rooney, Brian J. McHugh +14 more
2019Cancer Research110 citations Open access
Semantic Scholar
SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1.
S. Woodcock, C. Rooney, M. Liontos, Yvonne Connolly +4 more
2009Molecules and Cells89 citations Open access
Semantic Scholar
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)
S. Crabb, G. Griffiths, E. Marwood, D. Dunkley +20 more
2020Journal of Clinical Oncology71 citations Open access
Semantic Scholar
The Epithelial Cell and Lung Cancer: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer
C. Rooney, T. Sethi
2011Respiration68 citations Open access
Semantic Scholar
STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap
Anna Woroniuk, Andrew P. Porter, Gavin R. M. White, Daniel Newman +9 more
2018Nature Communications56 citations Open access
Semantic Scholar
Social media and palliative medicine: a retrospective 2-year analysis of global Twitter data to evaluate the use of technology to communicate about issues at the end of life
A. Nwosu, M. Debattista, C. Rooney, S. Mason
2014BMJ Supportive & Palliative Care46 citations
Semantic Scholar
Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.
E. Smyth, N. Turner, C. Peckitt, A. Pearson +16 more
201543 citations
Semantic Scholar
pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry
Gemma N. Jones, C. Rooney, Nicola Griffin, M. Roudier +16 more
2018British Journal of Cancer35 citations Open access
Semantic Scholar
Complexity of FGFR signalling in metastatic urothelial cancer
A. Rodríguez-Vida, M. Saggese, Simon Hughes, S. Rudman +8 more
2015Journal of Hematology & Oncology32 citations Open access
Semantic Scholar
The pathogenesis of mesothelioma is driven by a dysregulated translatome
Stefano Grosso, A. Marini, K. Gyurászová, J. V. Voorde +24 more
2021Nature Communications31 citations Open access
Semantic Scholar
A phase III trial of capivasertib and abiraterone versus placebo and abiraterone in patients with de novo metastatic hormone-sensitive prostate cancer characterized by PTEN deficiency (CAPItello-281).
K. Fizazi, D. George, M. De Santis, N. Clarke +8 more
202130 citations
Semantic Scholar
Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells
A. G. Trinidad, Nicky Whalley, R. Rowlinson, O. Delpuech +3 more
2017Oncogene30 citations Open access
Semantic Scholar
Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
O. Delpuech, C. Rooney, L. Mooney, D. Baker +11 more
2016Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon
C. Rooney, C. Geh, V. Williams, J. Heuckmann +11 more
2016PLoS ONE26 citations Open access
Semantic Scholar
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity.
A. Sacco, C. Federico, K. Todoerti, B. Ziccheddu +30 more
2021Blood20 citations Open access
Semantic Scholar
Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.
E. Smyth, N. Turner, A. Pearson, C. Peckitt +16 more
201620 citations
Semantic Scholar
Advances in molecular biology of lung disease: aiming for precision therapy in non-small cell lung cancer.
C. Rooney, T. Sethi
2015Chest19 citations
Semantic Scholar
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
V. Flemington, E. Davies, David M Robinson, Linda C. Sandin +26 more
2020Molecular Cancer Therapeutics18 citations
Semantic Scholar
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, E. Wigmore, S. Williamson, S. Ros +17 more
2023npj Breast Cancer17 citations Open access
Semantic Scholar
Exploratory biomarker analysis of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors.
E. Kilgour, D. Ferry, M. Saggese, H. Arkenau +12 more
201416 citations
Semantic Scholar
CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer.
S. Crabb, D. Ye, H. Uemura, T. Morris +5 more
2023Journal of Clinical Oncology13 citations
Semantic Scholar
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.
Bénédicte Delouvrié, K. Al-Kadhimi, J. Arnould, S. Barry +17 more
2012Bioorganic & Medicinal Chemistry Letters9 citations Open access
Semantic Scholar
Biomarkers for precision medicine in airways disease
C. Rooney, T. Sethi
2015Annals of the New York Academy of Sciences8 citations
Semantic Scholar
Asbestos accelerates disease onset in a genetic model of malignant pleural mesothelioma
Pooyeh Farahmand, K. Gyurászová, C. Rooney, X. Raffo-Iraolagoitia +14 more
2023Frontiers in Toxicology7 citations Open access
Semantic Scholar
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.
Bénédicte Delouvrié, K. Al-Kadhimi, J. Arnould, S. Barry +17 more
2012Bioorganic & Medicinal Chemistry Letters6 citations
Semantic Scholar
Galectin-3: A Central Regulator of Chronic Inflammation and Tissue Fibrosis
N. Henderson, A. Mackinnon, C. Rooney, T. Sethi
20126 citations
Semantic Scholar
Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma
A. Sacco, C. Federico, K. Todoerti, B. Ziccheddu +25 more
2019Blood4 citations Open access
Semantic Scholar
Updated overall survival (OS) analysis for ProCAID: A randomized, double-blind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC).
S. Crabb, G. Griffiths, D. Dunkley, N. Downs +11 more
2022Journal of Clinical Oncology3 citations
Semantic Scholar
A Phase 1b Open Label Multicentre Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
P. Paik, Rong-Rong Shen, M. Berger, D. Ferry +11 more
20173 citations
Semantic Scholar
145OPhase II study of AZD4547 in FGFR amplified tumours: gastroesophageal cancer (GC) cohort clinical and translational results
E. Smyth, N. Turner, A. Pearson, C. Peckitt +13 more
20153 citations Open access
Semantic Scholar
CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis
P. Stylianou, S. Rushwan, Wei Wang, M. Miah +21 more
2022bioRxiv2 citations Open access
Semantic Scholar
S45 VISTA expression in malignant pleural mesothelioma
C. Rooney, Colin Nixon, Kevin G. Blyth, T. Sethi +2 more
2019Novel insights into malignant pleural disease2 citations
Semantic Scholar
Exploring participants current experiences and opinions regarding use of music/dance in pulmonary rehabilitation
K. Philip, Sian Williams, J. Simpson, C. Rooney +3 more
20172 citations
Semantic Scholar
SOCIAL MEDIA AND PALLIATIVE MEDICINE: A TWO YEAR ANALYSIS OF GLOBAL TWITTER DATA
A. Nwosu, M. Debattista, C. Rooney, S. Mason
2014BMJ Supportive & Palliative Care2 citations Open access
Semantic Scholar
Therapeutics , Targets , and Chemical Biology AZD 4547 : An Orally Bioavailable , Potent , and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
P. Gavine, L. Mooney, E. Kilgour, A. Thomas +8 more
20122 citations
Semantic Scholar
Evaluating malignant pleural mesothelioma (MPM) sensitivity to inhibition of the Hippo pathway regulators NUAK1 and NUAK2
C. Rooney, W. Harrison, K. Gyurászová, D. Murphy
20201 citations
Semantic Scholar
P1.17-12 Colleague Peer Review of Radical Lung Radiotherapy Treatment Plans: The Impact on Interval from Decision to Treat to Treatment Delivery
C. Rooney, J. Mcaleese, L. Young, G. Walls +3 more
2018Journal of Thoracic Oncology1 citations Open access
Semantic Scholar
Faculty of 1000 evaluation for A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways.
T. Sethi, C. Rooney
20141 citations
Semantic Scholar
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
Lorna Hopcroft, E. Wigmore, S. Williamson, S. Ros +17 more
2023npj Breast Cancer0 citations Open access
Semantic Scholar
The Impact of PSMA PET-CT on Treatment Decisions in Prostate Cancer – Early Experience in a Single Centre
C. Rooney, A. Henry, A. Cole, J. O'Sullivan +2 more
20200 citations
Semantic Scholar
Faculty Opinions recommendation of Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
T. Sethi, C. Rooney
2019Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature0 citations
Semantic Scholar
Faculty Opinions recommendation of Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
T. Sethi, C. Rooney
2019Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature0 citations
Semantic Scholar
CD98hc : a potential treatment target in Malignant Mesothelioma
C. Rooney
20190 citations
Semantic Scholar
Curative Radiotherapy for Lung Cancer in the UK: International Benchmarking.
J. Mcaleese, C. Rooney, S. Baluch, K. Drinkwater +1 more
2019Clinics in oncology0 citations
Semantic Scholar
Abstract 1856: Combination of the novel ERK inhibitor AZD0364 with the MEK inhibitor selumetinib significantly enhances antitumor activity in KRAS mutant tumor models
V. Flemington, Iain Simpson, J. Breed, E. Davies +12 more
2018Experimental and Molecular Therapeutics0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Kilgour×12
Invite
E. Kilgour — researcher profile on SciRah
T. Sethi×10
Invite
T. Sethi — researcher profile on SciRah
N. Smith×9
Invite
N. Smith — researcher profile on SciRah
K. Al-Kadhimi×5
Invite
K. Al-Kadhimi — researcher profile on SciRah

×5

Invite

D. Baker — researcher profile on SciRah

Invite

P. Gavine — researcher profile on SciRah

Invite

A. Pearson — researcher profile on SciRah

Invite

E. Smyth — researcher profile on SciRah

Invite

C. Peckitt — researcher profile on SciRah

Invite

R. Cutts — researcher profile on SciRah

Invite

Gina Brown — researcher profile on SciRah

Invite

S. Chua — researcher profile on SciRah